ISSN:
1432-1440
Keywords:
Genital herpes
;
Herpes simplex virus
;
Leukocyte interferon-α
;
Venereal disease
;
Pharmaceutical creams
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract This double-blind, placebo-controlled study examined the clinical efficacy and tolerance of human leukocyte interferon-α (2 × 106 IU/g) in hydrophilic cream to cure patients afflicted with first episodes of genital herpes. Sixty patients aged 18–40 years (mean 24.5) with culture-confirmed herpes simplex genitalis, bearing 755 lesions (mean 12.6) were randomized to active and placebo groups. Patients joined the study within 7 days (mean 4.1) of the manifestation of lesions. Each patient was given a preceded 40-g tube containing placebo/active preparation with instructions on self-application of the trial medication to their lesions three times daily for 5 consecutive days (max. 15 topical applications per week). Patients were examined three times a week to evaluate clinical efficacy and other beneficial effects. A reepithelialized lesion with some residual erythema was recorded as healed. Patients resolved during the active treatment period (1–4 weeks) were spared further therapy and were requested to visit us as scheduled for posttreatment control after 16 weeks. From the remaining patients empty tubes were collected, and similarly coded replacement tubes were given to continue the treatment (in total 160 tubes were used). Patients treated with leukocyte interferon-α cream had significantly shorter mean duration of viral shedding/healing than placebo recipients, (6.2 days vs. 15 days; P 〈 0.01);thus the number of healed patients was 25/30 (83.3%) vs. 5/30 (17%); P 〈0.001. Of the 60 patients 49 (81.6%) complained no drug-related side effects. Transitory increase in body temperature (〉38°C) accompanied by mild headache, malaise, and myalgia were experienced by 11 (18.3%) patients; however, treatment was well tolerated by all the patients, and there were no dropouts. After 16 weeks only the cured patients were monitored on a monthly basis up to 20 months. Three (10%) cured patients showed recurrence after 22 months. In conclusion, the clinical results demonstrated that human leukocyte interferon-a (2 × 106 IU/g) in hydrophilic cream is more efficacious than placebo, and further support the adequacy of leukocyte interferon-α therapy as an effective and reliable treatment to cure first-episode genital herpes in women.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00198242
Permalink
